Trial Profile

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary) ; MK 2206 (Primary) ; Selumetinib (Primary) ; Sorafenib (Primary)
Indications Non-small cell lung cancer
Focus Biomarker; Therapeutic Use
Acronyms BATTLE-2

Most Recent Events

01 Dec 2020 Status changed from active, no longer recruiting to completed.
14 Feb 2020 Results assessing relation between STING pathway activation and anti-tumor immunity in Non-small cell lung cancer in two NSCLC cohorts from (treatment-naive-PROSPECT; relapsed-BATTLE-2) and The Cancer Genome Atlas (total n=1320) published in the Journal of Thoracic Oncology.
13 May 2019 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com